NEWS

Kizoo invests in Rejuvenation Startup MoglingBio

MoglingBio

Berlin/Ulm, Germany – MoglingBio, a privately held biotech company, announces today that it has successfully completed its first seed investment round. Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focused on startups reversing age-related damage on a cellular and molecular level.

Read More

Rejuvenation Startup Summit premieres October, 14-15, 2022 in Berlin

Rejuvenation Startup Summit

The Forever Healthy Foundation is pleased to announce the world’s first Rejuvenation Startup Summit will be held October 14-15, 2022 in Berlin.

The Rejuvenation Startup Summit is a vibrant networking event for rejuvenation startups, longevity investors, and translational researchers, and aims to accelerate the development of the rejuvenation biotech industry.

Startups will be able to connect with investors in the longevity space, present their approach, and get them interested in their work. Investors can meet the most promising rejuvenation startups from all over the world and get in touch with them straight away. Researchers with a startup itch can learn how to successfully break out of the lab and found or join a rejuvenation startup.

The summit brings together all those working on therapies that aim to vastly extend the healthy human lifespan. In addition to an exciting range of keynotes speeches, presentations, and panels, the summit features an all-day startup forum for easy networking. Starting midday on Friday and finishing off on Saturday night with a big party, it offers ample opportunity to connect, learn and network with the most relevant players in the field.

The Rejuvenation Startup Summit is not only open to startups, investors, and translational scientists – all interested members of the broader longevity movement, scientists from related fields, aspiring students, and the general media are also welcome.

Learn more at: https://forever-healthy.org/summit

Read More

Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round

Matthias Breugelmans and Naren Vyavahare
Dr. Breugelmans and Prof. Dr. Vyavahare

Greenville, SC, U.S. – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, today announced the closing of a $10 million funding round led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch. Elastrin Therapeutics was founded in 2018 as a spin-out from Clemson University, where the technology was first developed over a 20-year period.

Read More

Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Aaron Cravens Portrait
Dr. Aaron Cravens

San Francisco, CA, U.S. – Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies, and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.

Read More

Kizoo Portfolio Company Staffbase Raises $115M at $1.1B Valuation to Achieve Global Leadership in Employee Communications Management

Banner Employee Communication Management

Chemnitz / Munich / New York – March 15, 2022 – Kizoo Portfolio Company Staffbase, a leading provider of employee communications management solutions, today announced a $115M (€106M) Series E financing round led by General Atlantic, a leading global growth equity firm. Staffbase will leverage the new funds to help scale internationally and strengthen its global leadership in the internal communications space. Existing investor Insight Partners also participated in the round.

Read More

Kizoo portfolio company LIfT BioSciences secures its largest financing to date with a further £5m

Hands forming a heart

London, UK ­– Kizoo portfolio company Biotech LIfT BioSciences today announced its largest financing round to date with a further £5m investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. The round was led by new investor Starbloom Capital with additional participation by Jonathan Milner, a leading biotech ‘super-angel’ investor and earlier stage investor in LIfT, Kizoo Technology Ventures, a leading early-stage investor in breakthrough rejuvenation technologies and Downing Ventures, a leading London-based investor.

Read More

Kizoo portfolio company Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

elastrin adboard

Greenville, South Carolina, USA – Kizoo portfolio company Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board will help the company support its technology development by bringing unique perspectives and is comprised of leading industry and university experts in cardiovascular research and clinical development.

Read More

Kizoo portfolio company Mambu raises US$266 million at US$5.5 billion valuation

Logo Mambu

Kizoo portfolio company Mambu, a market-leading, modern SaaS banking platform, has announced raising $266 million in an EQT Growth-led Series E funding round, the largest financing round to date for a banking software platform. The funding brings the company’s valuation to $5.5 billion post money, making it one of the highest-valued B2B SaaS companies founded in Europe.

Read More

Kizoo portfolio company Underdog closes $10M financing round

Logo Underdog

Mountain View, CA, U.S., September 23, 2021 – Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.

Read More

Kizoo portfolio company Underdog awarded ‘Innovation Passport’ by UK Regulators

Logo Underdog

Mountain View, CA, U.S., September 08, 2021 – Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo is one of the first companies to be awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke.

Read More